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Summary. Preeclampsia complicates between 4–5 percent of pregnancies and it is one of the leading causes of maternal 
and perinatal mortality and morbidity worldwide. One potential screening tool for identifying pregnant women at risk 
for developing pre-eclampsia is Doppler assessment of blood flow in uterine arteries (UtA) and some other parts of 
uteroplacental circulation. Studies suggest that abnormal UtA waveforms (abnormal resistance index (RI), pulsatility 
index (PI) or diastolic notching) reflects impaired uteroplacental blood flow due to failed second wave of trophoblastic 
invasion of spiral arteries, and identify women at high risk of developing preeclampsia. Still, due to high false-positive 
rates, low sensitivity and low positive predictive values the majority of internatinational guidelines do not recommend 
the use of UtA Doppler in clinical practice. Until more evidence, perinatal care should still focus on taking a detailed 
medical history, assessing for risk factors and measuring blood pressure at each prenatal visit and if classified as high 
risk, to use some other screening methods. Also, a growing amount of evidence suggests that pregnant women presenting 
with one recognized high risk factors or two or more moderate risk factors for developing pre-eclampsia should be 
 offered low-dose aspirin from 12 weeks gestation in order to reduce the risk of developing preeclampsia.
introduction
Preeclampsia is a pregnancy related condition de-
fined as new onset hypertension after 20 weeks of gesta-
tion and coexistence of proteinuria (spot urine protein/
creatinine >30 mg/mmol or >300 mg/day or ≥1 g/L (2+) 
on dipstick testing) or other maternal organ dysfunction 
including renal insufficiency (creatinine 90 umol/L or 
more), liver involvement (AST or ALT over 40 U/L), 
neurological complications (eclampsia, altered mental 
status, headache, scotomata), hematological complica-
tions (platelet count below 150000/mL), hemolysis or 
disseminated intravascular coagulation (DIC) (1). Pre-
eclampsia is also complicated by uteroplacental dys-
function presumed by intrauterine fetal growth restric-
tion (IUGR) and/or abnormal umbilical artery Doppler 
studies (1). This definition is part of classification of 
hypertensive disorders in pregnancy which has last 
been updated in year 2000 and accepted with some mi-
nor alterations by the majority of obstetric societies 
worldwide (2–6).
Preeclampsia complicates around 4.6 % of pregnan-
cies (7) and it is more prevalent in first pregnancies and 
among women at the extremes of child bearing age (8). 
It is one of the leading causes of maternal and perinatal 
mortality and morbidity, especially in low income coun-
tries (4). Maternal morbidity includes development of 
stroke, eclampsia (eclamptic seizures) or organ failure 
as well as increased risk of development of cardiovas-
cular diseases later in life (9,10), while perinatal mor-
bidity includes intrauterine growth restriction, low birth 
weight, preterm birth and stillbirth (11).
screening for preeclampsia
Screening and early diagnosis of preeclampsia and 
other hypertensive disorders in pregnancy is important 
since the majority of deaths and certain morbidities re-
lated to preeclampsia could potentially be avoided or 
alleviated. This implies that women at increased risk for 
developing pre-eclampsia or diagnosed with preeclamp-
sia are provided appropriate and timely prenatal care, 
management, surveillance and treatment (12). A sys-
tematic review and meta-analysis published in 2016 
concluded that a past history of preeclampsia, preexist-
ing hypertension, pregestational diabetes, multifetal ges-
tation, chronic kidney disease, and some autoimmune 
diseases (primary antiphospholipid syndrome (PAPS), 
systemic lupus erythematosus (SLE) carry the highest 
relative risk of developing preeclampsia (13). These six 
risk factors listed above, carry an absolute risk for de-
veloping preeclampsia of at least 8 percent and have 
been endorsed by several international guidelines 
(Americal College of Obstetricians and Gynecologists 
(ACOG), United States Preventive Services Task Force 
(USPSTF), Up to Date and others to define women at 
high risk for developing preeclampsia (14–16). Studies 
have shown that these women would benefit from anti-
platelet therapy with low dose aspirin (LDA) started at 
12 to 16 weeks gestation, which effectively and safely 
prevents preeclampsia and other associated complica-
tions (IUGR and preterm birth) (17). International 
guidelines strongly recommend the use of LDA from 
late first trimester to treat women at high risk of pre-
eclampsia, but somewhat differ regarding definition of 
high risk factors of preeclampsia (3,15). LDA should be 
initiated between 12 and 28 gestational weeks (optimal-
ly before 16 gestational weeks) and continued until de-
livery (15,16). Of note, ACOG, USPSTF, Up to date 
recommend LDA of 81mg/day, while National Institute 
for Health and Care Exelence (NICE), World Health 
Organization (WHO) and Society of Obstetricians and 
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Gynecologists of Canada (SOCG) recommend 75mg/
day (18). There is less consensus regarding criteria that 
confer moderate risk for developping preeclampisa. 
ACOG, USPSTF and Up to date recommend intiation 
of LDA for preeclampsia prevention to women with 
two or more moderate risk factors which include nulli-
parity, obesity (body mass index >30 kg/m2), family 
history of preeclampsia in mother or sister, age ≥35 
years, sociodemographic characteristics (African Amer-
ican race, low socioeconomic level) and personal risk 
factors (ie. previous pregnancy with low birth weight or 
small for gestational age infant, previous adverse preg-
nancy outcome [eg, stillbirth], interval >10 years be-
tween pregnancies) (14–16). Moderate risk factors en-
doursed by NICE include age ≥40 years, first pregnan-
cy, multiple gestation, >10 years between pregnancies, 
body mass index ≥35 kg/m2 at presentation, family his-
tory of preeclampsia. Presence of 2 or more indicate 
initiation of LDA (19). All pregnant women should be 
screened for these high and moderate risk factors for 
development of preeclampisa at the first prenatal visit 
and managed accordingly. Transfer to secondary or ter-
tiary health care centers, prophylactic administration of 
steroids for fetal lung maturation in pre-term pregnan-
cies are just two of many other interventions that can be 
implemented in order to improve management of preg-
nant women at risk for pre-eclampsia.
Many different laboratory tests have also been pro-
posed for screening for preeclampsia, but none of them 
have achieved satisfying sensitivity or specificity to be 
included in routine prenatal care. These include various 
angiogenic modulators and growth factors (PIGF, 
VEGF, sFIt-1), maternal serum analyses concentrations 
(pregnancy-associated plasma protein A) and abnor-
malities in cell-free DNA quantifications which all lack 
adequate statistical and clinical relevance (20–23).
Uteroplacental blood flow  
and risk of developing preeclampsia
In the past 30 years a great amount of research on 
ultrasound Doppler has confirmed the association be-
tween increased blood flow resistance in uteroplacental 
circulation i.e. uterine arteries and its branches and ele-
vated risk of development of obstetric complications 
related to uteroplacental insufficiency (24,25). These 
mainly include hypertensive disorders of pregnancy, 
notably preeclampsia, but also intrauterine growth re-
striction, small for gestational age babies, Hemolysis, 
ELevated liver function test and Low Platelets (HELLP) 
syndrome, placental abruption and others (26,27). In-
creased resistance in uterine artery is a reflection of im-
paired uteroplacental blood flow. This is a consequence 
thought to occur secondarily to failed second wave of 
trophoblastic invasion of spiral arteries resulting in ab-
normal placental formation (28,29). In normal pregnan-
cies, placental trophoblast cells invade the inner third of 
the myometrium and change highly resistant spiral ar-
teries (as terminal branches of uterine arteries) into low-
resistance vessels. This vascular remodeling is reflected 
by high diastolic velocity and continuous flow during 
diastolic part of cardiac cycle in uterine artery Doppler 
studies (30,31). In women who develop adverse preg-
nancy outcomes attributed to uteroplacental insufficien-
cy, myometrial arterioles are only partially invaded 
which is termed failed trophoblastic invasion of spiral 
arteries. Spiral arteries do not loose their endothelial 
lining and musculoelastic tissue and their mean external 
diameter becomes only half of that of corresponding 
vessels in the normal placental bed (32). Such spiral ar-
teries have an abnormally narrow lumen resulting in 
high resistance to blood flow, resulting in abnormally 
high resistance in proximal parts of uteroplacental cir-
culation (i.e. uterine arteries (UtA) and impaired pla-
cental blood flow.
Most often studied Doppler abnormalities of UtA 
waveforms are elevated UtA resistance index (RI) and 
pulsatility index (PI). There are several definitions of 
their abnormality but most commonly used ones, RI ≥ 
0.58, PI ≥ 1.60 or both above 90th centile were sug-
gested as they were shown to represent a higher risk of: 
preterm birth before 32 weeks of gestation, develop-
ment of severe preeclampsia, intrauterine growth re-
striction, HELLP syndrome, oligohydramnios presence, 
placental insufficiency and placental abruption (27). 
Other abnormalities of UtA waveforms related to ad-
verse pregnancy outcomes due to impaired uteroplacen-
tal circulation is presence of mid-trimester diastolic 
notching (33), or presence of peak systolic over end dia-
stolic velocities ratio (A:B ratio) > 90th centile, which 
was found to be significantly associated with develop-
ment of preeclampsia and small for gestational age in-
fants (33). In the majority of studies, all UtA Doppler 
indices perform similarly when evaluated in the second 
trimester (34,35), but a systematic review and meta 
analysis including almost 80,000 women concluded 
that pulsatility index, alone or combined with notching 
was most predictive Doppler index and it is the only one 
possibly of use in clinical practice (36). The majority of 
above mentioned research has been performed in preg-
nancies between 17 and 22 gestational weeks, defined 
as the period of second wave of trophoblastic invasion. 
However, studies have reported this association to be 
present as early as in the first trimster, i.e. at 12 weeks 
gestation (37,38).
According to a reveiw by Papageorghiou et al., in-
creased impedance to flow in UtA in pregnancies at-
tending routine antenatal care identifies about 40% of 
asymptomatic women who will subsequently develop 
preeclampsia and following a positive test, the likeli-
hood of developing pre-eclampsia is increased by about 
6 times (39). On the other hand, women with normal 
UtA Doppler at 20 weeks’ gestation have a low risk of 
developing obstetric complications related to uteropla-
cental insufficiency (40). A study by Coomarasamy et 
al. suggests that prophylactic LDA therapy before 16 
gestational weeks in women identified as being at risk 
of developing preeclampsia using UtA Doppler assess-
ment results in a significant reduction in preterm pre-
eclampsia (41). A systematic review and meta analysis 
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by Cnossen et al. describes that increased UtA pulsatil-
ity index with notching is predictive of developing pre-
eclampsia and has a positive likelihood ratio 21.0 
among high risk patients and 7.5 among low risk pa-
tients (36). Another meta analysis by Kleinrouweler et 
al. supports adding UtA Doppler measurements to other 
patients characteristics (blood pressure or BMI) in iden-
tification of women at risk for preeclampsia (42).
Despite these significant associations and two above 
mentioned meta analyses from 2008 and 2013 support-
ing the use of UtA Doppler in clinical practice; (36,42) 
WHO, Up to Date and some other studies emphasize 
that UtA Doppler ultrasound should not be used in rou-
tine second trimester antenatal care as a screening 
method due to high false-positive rates (43,44). UtA 
Doppler has low positive predictive values being be-
tween 4 and 29%.(29,45) In a study of Irion et al., UtA 
Doppler abnormalities had low sensitivities ranging 
from 26% to 34% and low positive predictive values 
form 7% to 28% for predicting preeclampsia, low birth-
weight and prematurity in low risk nuliparous women 
(34). Also, in a study by Li et al., only one third of 
women with preeclampsia showed signs of increased 
UtA vascular impedance in the third trimester (46). On 
the other hand, UtA Doppler waveform analysis may be 
useful in selected high risk populations. In women iden-
tified to be at high risk for pre-eclampsia and/or SGA 
babies, UtA Doppler waveform performed between 22 
and 24 weeks gestation, i.e. after second wave of tro-
phoblast invasion; predicted severe adverse pregnancy 
outcomes and was better than clinical risk assessment in 
prediction of preeclampsia and SGA babies (29). UtA 
Doppler studies have also been shown to have a higher 
accuracy in identifying patients who will subsequently 
develop early rather than late-onset pre-eclampsia, 
which might be a focus in future research (47,48).
Up to Date points out that all these data need to be 
interpreted with caution, as studies of UtA Doppler ve-
locimetry for prediction of preeclampsia are difficult to 
compare because investigators have used different Dop-
pler sampling techniques and different definitions of 
abnormal flow velocity waveform, have assessed differ-
ent populations with differing, gestational age at exami-
nation, and criteria for diagnosis of preeclampsia (44). 
Recent ACOG recommendations define women at high 
or moderate risk for developing preeclampsia that 
would benefit from LDA therapy and do not include 
UtA Doppler assessment (14).
The debate whether to use UtA Doppler in routine 
prenatal care for screening for obstetric complications 
related to uteroplacental insufficiency remains incon-
clusive.
conclusion
Doppler assessment of blood flow in uteroplacental 
circulation is a potential screening tool for selecting 
pregnant women at high risk for developing some ad-
verse pregnancy outcomes, including preeclampsia. 
However, results from studies are inconclusive as well 
as recommendations for clinical use and further re-
search is mandatory to estimate and entirely compre-
hend different screening methods (49). It should always 
be kept in mind that preeclampsia cannot reliably be 
predicted in the general as well as high risk population, 
and perinatal care should still focus on taking a detailed 
medical history, assessing for risk factors and measur-
ing blood pressure at each prenatal visit (44,50). There 
is a growing amount of evidence and recommendations 
suggesting that pregnant women presenting with one 
recognized high risk factors or two or more moderate 
risk factors for developing pre-eclampsia should be of-
fered low dose aspirin from 12 weeks gestation to re-
duce the risk of developing preeclampsia.
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Doplerska analiza  
uteroplacentarnog protoka  
u probiru za preeklampsiju
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Pregledni članak
Ključne riječi: Preeklampsija, dopler uterine arterije, prevencija
Sažetak. Preeklampsija je poremećaj koji zahvaća 4–5% trudnoća i predstavlja jedan od vodećih uzroka majčinog i 
perinatalnog mortaliteta i morbiditeta diljem svijeta. Kvalitetan probir i rano prepoznavanje trudnica s povećanim 
 rizikom od razvoja preeklampsije od velike su važnosti zbog mogućnosti izbjegavanja ili ublažavanja povećanog mor-
taliteta i morbiditeta koji ju prate. Najšire prihvaćena metoda rane dijagnostike preeklampsije predstavlja mjerenje 
krvnog tlaka na svakom antenatalnom pregledu, ali uz znatno reduciranu mogućnost ranog probira. Anamnestički poda-
ci koji svrstavaju trudnice u skupinu s visokim rizikom za razvoj preeklampsije su: razvoj preeklampsije u prethodnoj 
trudnoći, arterijska hipertenzija ili šećerna bolest prije trudnoće, višeplodna trudnoća, kronična bubrežna bolest i 
određene autoimune bolesti (sistemski eritemski lupus i antifosfolipidni sindrom).
Jedna od brojnih metoda probira jest korištenje ultrazvučne tehnologije, odnosno analize protoka uteroplacentarne 
cirkulacije doplerom. Dokazana je povezanost između povišenog otpora u uterinim arterijima i povećanog rizika od 
razvoja patoloških stanja trudnoće povezanih s uteroplacentarnom insuficijencijom, poput hipertenzivnih poremećaja u 
trudnoći (naročito preeklampsije), zastoja u rastu ploda, HELLP sindroma, abrupcije posteljice i drugih. Povišen otpor 
protoku krvi u uterinoj arteriji odraz je poremećaja protoka krvi u njenom distalnom vaskularnom bazenu koji je 
 posljedica abnormalne placentacije, odnosno nepotpune invazije trofoblasta u spiralne arterije. Istražene su različite 
promjene doplerskog vala uterine arterije poput indeksa otpora (s graničnom vrijednosti RI ≥ 0,58), indeksa pulsatilnosti 
(s graničnom vrijednosti PI ≥ 1,60) i postojanja dijastoličkog ureza. Neovisno o izmjerenim vrijednostima, većina 
istraživanih parametara pokazala je sličnu uspješnost u ranom probiru. Brojna istraživanja pokazuju kako se patološki 
doplerski zapis uterine arterije u drugom tromjesečju trudnoće povezuje s razvojem preeklampsije, dok njen uredan za-
pis s relativno velikom sigurnošću otklanja postojanje rizika od razvoja patoloških stanja povezanih s uteroplacentarnom 
insuficijencijom. Unatoč navedenom, većina međunarodnih društava u svojim smjernicama i dalje ne preporuča rutinsko 
korištenje ultrazvučne doplerske tehnike uterine arterije u kliničkom radu zbog njene relativno niske osjetljivosti (do 
35%), niske pozitivne prediktivne vrijednosti (između 7 i 30%) te velikog broja lažno pozitivnih rezultata.
U skladu s navedenim, rasprava treba li koristiti tehniku doplera uterine arterije kao metodu probira drugog tromjesečja 
u razvoju preeklampsije ostaje i dalje otvorena te su potrebna dodatna istraživanja u svrhu potpune procjene njene 
učinkovitosti. Razvoj preeklampsije i dalje se ne može pouzdano predvidjeti niti u općoj, niti u visoko rizičnoj popula-
ciji, te se antenatalna skrb u ovom pogledu i dalje temelji na kvalitetno uzetoj anamezi, procjeni čimbenika rizika i 
mjerenju krvnog tlaka prilikom svakog pregleda. Raste broj istraživanja i preporuka koje ukazuju kako bi trudnice koje 
imaju jedan od visoko rizičnih čimbenika, ili dva ili više srednje rizičnih čimbenika, trebale profilaktički primati male 
doze acetilsalicilne kiseline od 12. tjedna trudnoće, a u svrhu smanjenja rizika od razvoja preeklampsije.
